Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 391

1.

Optimized scoring tool to quantify the functional performance during the sit-to-stand transition with a magneto-inertial measurement unit.

Lepetit K, Mansour KB, Letocart A, Boudaoud S, Kinugawa K, Grosset JF, Marin F.

Clin Biomech (Bristol, Avon). 2019 Oct;69:109-114. doi: 10.1016/j.clinbiomech.2019.07.012. Epub 2019 Jul 11.

PMID:
31330459
2.

Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.

Saini V, Ammerman NC, Chang YS, Tasneen R, Chaisson RE, Jain S, Nuermberger E, Grosset JH.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00388-19. doi: 10.1128/AAC.00388-19. Print 2019 Jun.

3.

Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.

Almeida DV, Omansen TF, Li SY, Lee J, Grosset JH, Converse PJ, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02171-18. doi: 10.1128/AAC.02171-18. Print 2019 Mar.

4.

High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.

Omansen TF, Almeida D, Converse PJ, Li SY, Lee J, Stienstra Y, van der Werf T, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01478-18. doi: 10.1128/AAC.01478-18. Print 2019 Feb.

5.

An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+.

Mieras LF, Taal AT, van Brakel WH, Cambau E, Saunderson PR, Smith WCS, Prakoeswa CRS, Astari L, Scollard DM, do Nascimento DC, Grosset J, Kar HK, Izumi S, Gillini L, Virmond MCL, Sturkenboom MGG.

BMC Infect Dis. 2018 Oct 5;18(1):506. doi: 10.1186/s12879-018-3402-4.

6.

Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.

Converse PJ, Almeida DV, Tasneen R, Saini V, Tyagi S, Ammerman NC, Li SY, Anders NM, Rudek MA, Grosset JH, Nuermberger EL.

PLoS Negl Trop Dis. 2018 Aug 13;12(8):e0006728. doi: 10.1371/journal.pntd.0006728. eCollection 2018 Aug.

7.

Biomaterials in Tendon and Skeletal Muscle Tissue Engineering: Current Trends and Challenges.

Beldjilali-Labro M, Garcia Garcia A, Farhat F, Bedoui F, Grosset JF, Dufresne M, Legallais C.

Materials (Basel). 2018 Jun 29;11(7). pii: E1116. doi: 10.3390/ma11071116. Review.

8.

C-reactive protein as a screening test for HIV-associated pulmonary tuberculosis prior to antiretroviral therapy in South Africa.

Shapiro AE, Hong T, Govere S, Thulare H, Moosa MY, Dorasamy A, Wallis CL, Celum CL, Grosset J, Drain PK.

AIDS. 2018 Aug 24;32(13):1811-1820. doi: 10.1097/QAD.0000000000001902.

9.

Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.

Ammerman NC, Swanson RV, Bautista EM, Almeida DV, Saini V, Omansen TF, Guo H, Chang YS, Li SY, Tapley A, Tasneen R, Tyagi S, Betoudji F, Moodley C, Ngcobo B, Pillay L, Bester LA, Singh SD, Chaisson RE, Nuermberger E, Grosset JH.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00636-18. doi: 10.1128/AAC.00636-18. Print 2018 Jul.

10.

Water deprivation decreases strength in fast twitch muscle in contrast to slow twitch muscle in rat.

Farhat F, Grosset JF, Canon F.

Acta Physiol (Oxf). 2018 Sep;224(1):e13072. doi: 10.1111/apha.13072. Epub 2018 Apr 23.

PMID:
29633518
11.

Investigation of the HD-sEMG probability density function shapes with varying muscle force using data fusion and shape descriptors.

Al Harrach M, Boudaoud S, Carriou V, Laforet J, Letocart AJ, Grosset JF, Marin F.

Comput Biol Med. 2017 Oct 1;89:44-58. doi: 10.1016/j.compbiomed.2017.07.023. Epub 2017 Aug 1.

PMID:
28783537
12.

Skeletal muscle morphology and regulatory signalling in endurance-trained and sedentary individuals: The influence of ageing.

Mikkelsen UR, Agergaard J, Couppé C, Grosset JF, Karlsen A, Magnusson SP, Schjerling P, Kjaer M, Mackey AL.

Exp Gerontol. 2017 Jul;93:54-67. doi: 10.1016/j.exger.2017.04.001. Epub 2017 Apr 12.

PMID:
28411009
13.

Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo.

Ammerman NC, Swanson RV, Tapley A, Moodley C, Ngcobo B, Adamson J, Dorasamy A, Moodley S, Mgaga Z, Bester LA, Singh SD, Almeida DV, Grosset JH.

J Antimicrob Chemother. 2017 Feb;72(2):455-461. doi: 10.1093/jac/dkw417. Epub 2016 Oct 25.

PMID:
27798204
14.

The Differential Hormonal Milieu of Morning versus Evening May Have an Impact on Muscle Hypertrophic Potential.

Burley SD, Whittingham-Dowd J, Allen J, Grosset JF, Onambele-Pearson GL.

PLoS One. 2016 Sep 1;11(9):e0161500. doi: 10.1371/journal.pone.0161500. eCollection 2016.

15.

Denoising of HD-sEMG signals using canonical correlation analysis.

Al Harrach M, Boudaoud S, Hassan M, Ayachi FS, Gamet D, Grosset JF, Marin F.

Med Biol Eng Comput. 2017 Mar;55(3):375-388. doi: 10.1007/s11517-016-1521-x. Epub 2016 May 25.

PMID:
27221811
16.

Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.

Almeida D, Ioerger T, Tyagi S, Li SY, Mdluli K, Andries K, Grosset J, Sacchettini J, Nuermberger E.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4590-9. doi: 10.1128/AAC.00753-16. Print 2016 Aug.

17.

Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance.

Desjardins CA, Cohen KA, Munsamy V, Abeel T, Maharaj K, Walker BJ, Shea TP, Almeida DV, Manson AL, Salazar A, Padayatchi N, O'Donnell MR, Mlisana KP, Wortman J, Birren BW, Grosset J, Earl AM, Pym AS.

Nat Genet. 2016 May;48(5):544-51. doi: 10.1038/ng.3548. Epub 2016 Apr 11.

18.

Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.

Swanson RV, Ammerman NC, Ngcobo B, Adamson J, Moodley C, Dorasamy A, Moodley S, Mgaga Z, Bester LA, Singh SD, Almeida DV, Grosset JH.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2864-9. doi: 10.1128/AAC.00177-16. Print 2016 May.

19.

Human Achilles tendon glycation and function in diabetes.

Couppé C, Svensson RB, Kongsgaard M, Kovanen V, Grosset JF, Snorgaard O, Bencke J, Larsen JO, Bandholm T, Christensen TM, Boesen A, Helmark IC, Aagaard P, Kjaer M, Magnusson SP.

J Appl Physiol (1985). 2016 Jan 15;120(2):130-7. doi: 10.1152/japplphysiol.00547.2015. Epub 2015 Nov 5.

20.

Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.

Cohen KA, Abeel T, Manson McGuire A, Desjardins CA, Munsamy V, Shea TP, Walker BJ, Bantubani N, Almeida DV, Alvarado L, Chapman SB, Mvelase NR, Duffy EY, Fitzgerald MG, Govender P, Gujja S, Hamilton S, Howarth C, Larimer JD, Maharaj K, Pearson MD, Priest ME, Zeng Q, Padayatchi N, Grosset J, Young SK, Wortman J, Mlisana KP, O'Donnell MR, Birren BW, Bishai WR, Pym AS, Earl AM.

PLoS Med. 2015 Sep 29;12(9):e1001880. doi: 10.1371/journal.pmed.1001880. eCollection 2015 Sep.

21.

Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins.

Kling A, Lukat P, Almeida DV, Bauer A, Fontaine E, Sordello S, Zaburannyi N, Herrmann J, Wenzel SC, König C, Ammerman NC, Barrio MB, Borchers K, Bordon-Pallier F, Brönstrup M, Courtemanche G, Gerlitz M, Geslin M, Hammann P, Heinz DW, Hoffmann H, Klieber S, Kohlmann M, Kurz M, Lair C, Matter H, Nuermberger E, Tyagi S, Fraisse L, Grosset JH, Lagrange S, Müller R.

Science. 2015 Jun 5;348(6239):1106-12. doi: 10.1126/science.aaa4690.

PMID:
26045430
22.

Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.

Converse PJ, Tyagi S, Xing Y, Li SY, Kishi Y, Adamson J, Nuermberger EL, Grosset JH.

PLoS Negl Trop Dis. 2015 Jun 4;9(6):e0003823. doi: 10.1371/journal.pntd.0003823. eCollection 2015.

23.

A reader's guide to the bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.

Grosset J, Vernon A.

Am J Respir Crit Care Med. 2015 Apr 15;191(8):871-3. doi: 10.1164/rccm.201502-0367ED. No abstract available.

24.

Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis.

Swanson RV, Adamson J, Moodley C, Ngcobo B, Ammerman NC, Dorasamy A, Moodley S, Mgaga Z, Tapley A, Bester LA, Singh S, Grosset JH, Almeida DV.

Antimicrob Agents Chemother. 2015;59(6):3042-51. doi: 10.1128/AAC.00260-15. Epub 2015 Mar 9.

25.

Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.

Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH.

Antimicrob Agents Chemother. 2015 Apr;59(4):2129-35. doi: 10.1128/AAC.04841-14. Epub 2015 Jan 26.

26.

Evaluation of HD-sEMG Probability Density Function deformations in ramp exercise.

Al Harrach M, Boudaoud S, Gamet D, Grosset JF, Marin F.

Conf Proc IEEE Eng Med Biol Soc. 2014;2014:2209-12. doi: 10.1109/EMBC.2014.6944057.

PMID:
25570425
27.

Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.

Tyagi S, Ammerman NC, Li SY, Adamson J, Converse PJ, Swanson RV, Almeida DV, Grosset JH.

Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):869-74. doi: 10.1073/pnas.1416951112. Epub 2015 Jan 5.

28.

Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice.

Almeida DV, Tyagi S, Li S, Wallengren K, Pym AS, Ammerman NC, Bishai WR, Grosset JH.

Mycobact Dis. 2014 May 5;4:145.

29.

Life-long endurance running is associated with reduced glycation and mechanical stress in connective tissue.

Couppé C, Svensson RB, Grosset JF, Kovanen V, Nielsen RH, Olsen MR, Larsen JO, Praet SF, Skovgaard D, Hansen M, Aagaard P, Kjaer M, Magnusson SP.

Age (Dordr). 2014;36(4):9665. doi: 10.1007/s11357-014-9665-9. Epub 2014 Jul 5.

30.

Influence of exercise intensity on training-induced tendon mechanical properties changes in older individuals.

Grosset JF, Breen L, Stewart CE, Burgess KE, Onambélé GL.

Age (Dordr). 2014 Jun;36(3):9657. doi: 10.1007/s11357-014-9657-9. Epub 2014 Apr 24.

31.

Changes in contractile and elastic properties of the triceps surae muscle induced by neuromuscular electrical stimulation training.

Grosset JF, Canon F, Pérot C, Lambertz D.

Eur J Appl Physiol. 2014;114(7):1403-11. doi: 10.1007/s00421-014-2871-4. Epub 2014 Mar 20.

PMID:
24647638
32.

Accelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans disease.

Converse PJ, Xing Y, Kim KH, Tyagi S, Li SY, Almeida DV, Nuermberger EL, Grosset JH, Kishi Y.

PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2618. doi: 10.1371/journal.pntd.0002618. eCollection 2014.

33.

Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection.

Zhang T, Li SY, Converse PJ, Grosset JH, Nuermberger EL.

PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2598. doi: 10.1371/journal.pntd.0002598. eCollection 2013.

34.

Life-long endurance exercise in humans: circulating levels of inflammatory markers and leg muscle size.

Mikkelsen UR, Couppé C, Karlsen A, Grosset JF, Schjerling P, Mackey AL, Klausen HH, Magnusson SP, Kjær M.

Mech Ageing Dev. 2013 Nov-Dec;134(11-12):531-40. doi: 10.1016/j.mad.2013.11.004. Epub 2013 Nov 25.

PMID:
24287006
35.

Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207).

Grosset JH, Ammerman NC.

Expert Rev Anti Infect Ther. 2013 Jul;11(7):649-51. doi: 10.1586/14787210.2013.811848.

PMID:
23879605
36.

Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.

Grosset JH, Tyagi S, Almeida DV, Converse PJ, Li SY, Ammerman NC, Bishai WR, Enarson D, Trébucq A.

Am J Respir Crit Care Med. 2013 Sep 1;188(5):608-12. doi: 10.1164/rccm.201304-0753OC.

37.

Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.

Ahmad Z, Tyagi S, Minkowski A, Peloquin CA, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2013 Jul 1;188(1):97-102. doi: 10.1164/rccm.201212-2328OC.

38.

Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease.

Sarfo FS, Converse PJ, Almeida DV, Zhang J, Robinson C, Wansbrough-Jones M, Grosset JH.

PLoS Negl Trop Dis. 2013;7(3):e2101. doi: 10.1371/journal.pntd.0002101. Epub 2013 Mar 14.

39.

Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.

Almeida DV, Converse PJ, Li SY, Tyagi S, Nuermberger EL, Grosset JH.

PLoS Negl Trop Dis. 2013;7(2):e2085. doi: 10.1371/journal.pntd.0002085. Epub 2013 Feb 28.

40.

Comparative effect of a 1 h session of electrical muscle stimulation and walking activity on energy expenditure and substrate oxidation in obese subjects.

Grosset JF, Crowe L, De Vito G, O'Shea D, Caulfield B.

Appl Physiol Nutr Metab. 2013 Jan;38(1):57-65. doi: 10.1139/apnm-2011-0367. Epub 2012 Nov 12.

PMID:
23368829
41.

The chemotherapy of leprosy: an interpretive history.

Gelber RH, Grosset J.

Lepr Rev. 2012 Sep;83(3):221-40. No abstract available.

PMID:
23356023
42.

Reply to "Contradictory results with high-dosage rifamycin in mice and humans".

Nuermberger EL, Rosenthal IM, Tasneen R, Peloquin CA, Mdluli KE, Karakousis PC, Grosset JH.

Antimicrob Agents Chemother. 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12. No abstract available.

43.

Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.

Ahmad Z, Tyagi S, Minkowsk A, Almeida D, Nuermberger EL, Peck KM, Welch JT, Baughn AS, Jacobs WR Jr, Grosset JH.

Indian J Med Res. 2012 Nov;136(5):808-14.

44.

Neuromuscular electrical stimulation can elicit aerobic exercise response without undue discomfort in healthy physically active adults.

Crognale D, Vito GD, Grosset JF, Crowe L, Minogue C, Caulfield B.

J Strength Cond Res. 2013 Jan;27(1):208-15. doi: 10.1519/JSC.0b013e318252f5e5.

PMID:
23254490
45.

Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy.

Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH.

J Antimicrob Chemother. 2013 Mar;68(3):659-65. doi: 10.1093/jac/dks421. Epub 2012 Nov 5.

46.

Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide.

Grosset J, Almeida D, Converse PJ, Tyagi S, Li SY, Ammerman NC, Pym AS, Wallengren K, Hafner R, Lalloo U, Swindells S, Bishai WR.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15001-5. doi: 10.1073/pnas.1203636109. Epub 2012 Aug 27.

47.

Are H-reflex and M-wave recruitment curve parameters related to aerobic capacity?

Piscione J, Grosset JF, Gamet D, Pérot C.

Appl Physiol Nutr Metab. 2012 Oct;37(5):990-6. doi: 10.1139/h2012-078. Epub 2012 Aug 2.

PMID:
22857019
48.

New drugs for the treatment of tuberculosis: hope and reality.

Grosset JH, Singer TG, Bishai WR.

Int J Tuberc Lung Dis. 2012 Aug;16(8):1005-14. doi: 10.5588/ijtld.12.0277. Review.

PMID:
22762423
49.

Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2012 Aug;56(8):4331-40. doi: 10.1128/AAC.00912-12. Epub 2012 Jun 4.

50.

Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.

Dutta NK, Illei PB, Peloquin CA, Pinn ML, Mdluli KE, Nuermberger EL, Grosset JH, Karakousis PC.

Antimicrob Agents Chemother. 2012 Jul;56(7):3726-31. doi: 10.1128/AAC.00500-12. Epub 2012 Apr 30.

Supplemental Content

Loading ...
Support Center